(Q45212093)

10 December 2017

FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer (English)

1 reference

estrogen-receptor positive breast cancer

10 December 2017

0 references

1 reference

Mai Kawase

1

1 reference

10 December 2017

Tatsuya Toyama

2

1 reference

10 December 2017

Satoru Takahashi

3

1 reference

10 December 2017

Shinya Sato

4

1 reference

10 December 2017

Nobuyasu Yoshimoto

5

1 reference

10 December 2017

Yumi Endo

6

1 reference

10 December 2017

Tomoko Asano

7

1 reference

10 December 2017

Shunzo Kobayashi

8

1 reference

10 December 2017

Yoshitaka Fujii

9

1 reference

10 December 2017

Hiroko Yamashita

10

1 reference

10 December 2017

16 June 2013

1 reference

10 December 2017

1 reference

10 December 2017

22

1 reference

10 December 2017

3

1 reference

10 December 2017

308-316

1 reference

https://scigraph.springernature.com/pub.10.1007/s12282-013-0482-2

10 December 2017

0 references

cites work

Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS12282-013-0482-2

Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-013-0482-2

Neoadjuvant chemotherapy in breast cancer-insights from the German experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-013-0482-2

Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-013-0482-2

Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-013-0482-2

Neoadjuvant chemotherapy in ER+ HER2- breast cancer: response prediction based on immunohistochemical and molecular characteristics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-013-0482-2

Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-013-0482-2

Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-013-0482-2

Different prognostic significance of Ki-67 change between pre- and post-neoadjuvant chemotherapy in various subtypes of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-013-0482-2

Pathological complete response after preoperative systemic therapy and outcome: relevance of clinical and biologic baseline features.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-013-0482-2

Forkhead-box A1 (FOXA1) expression in breast cancer and its prognostic significance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-013-0482-2

FOXA1 is an independent prognostic marker for ER-positive breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-013-0482-2

Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-013-0482-2

BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-013-0482-2

Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-013-0482-2

The role of Tau protein in resistance to paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-013-0482-2

Evaluation of prognostic and predictive value of microtubule associated protein tau in two independent cohorts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-013-0482-2

Evaluation of microtubule-associated protein-Tau expression as a prognostic and predictive marker in the NSABP-B 28 randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-013-0482-2

Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-013-0482-2

Predictors of response to exemestane as primary endocrine therapy in estrogen receptor-positive breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-013-0482-2

miR-1290 and its potential targets are associated with characteristics of estrogen receptor α-positive breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-013-0482-2

New developments in hormone receptor-positive disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-013-0482-2

Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-013-0482-2

Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-013-0482-2

Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-013-0482-2

FOXA1 is a key determinant of estrogen receptor function and endocrine response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12282-013-0482-2

10.1007/S12282-013-0482-2

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

10 December 2017

0 references

1 reference